HK1104295A1 - Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs) - Google Patents

Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs)

Info

Publication number
HK1104295A1
HK1104295A1 HK07109577.5A HK07109577A HK1104295A1 HK 1104295 A1 HK1104295 A1 HK 1104295A1 HK 07109577 A HK07109577 A HK 07109577A HK 1104295 A1 HK1104295 A1 HK 1104295A1
Authority
HK
Hong Kong
Prior art keywords
improved
gpcrs
ligands
protein coupled
coupled receptors
Prior art date
Application number
HK07109577.5A
Other languages
English (en)
Inventor
K Paulini
M Gerlach
E Gunther
E Polymeropoulos
S Baasner
P Schmidt
R Kuhne
A Soderhall
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HK1104295A1 publication Critical patent/HK1104295A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07109577.5A 2004-07-14 2007-09-04 Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs) HK1104295A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58796904P 2004-07-14 2004-07-14
DE102004033902A DE102004033902A1 (de) 2004-07-14 2004-07-14 Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
US68317805P 2005-05-20 2005-05-20
PCT/EP2005/007255 WO2006005484A1 (fr) 2004-07-14 2005-07-05 Nouveaux derives de tetrahydrocarbazole a effet biologique et solubilite ameliores comme ligands pour des recepteurs couples aux proteines g (rcpgs)

Publications (1)

Publication Number Publication Date
HK1104295A1 true HK1104295A1 (en) 2008-01-11

Family

ID=35045230

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109577.5A HK1104295A1 (en) 2004-07-14 2007-09-04 Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs)

Country Status (26)

Country Link
US (2) US7375127B2 (fr)
EP (2) EP1995238A3 (fr)
JP (1) JP4746617B2 (fr)
KR (1) KR100888895B1 (fr)
CN (1) CN1997629B (fr)
AR (1) AR050347A1 (fr)
AT (1) ATE406352T1 (fr)
AU (1) AU2005261930B2 (fr)
BR (1) BRPI0513209A (fr)
CA (1) CA2565850C (fr)
CY (1) CY1110415T1 (fr)
DE (2) DE102004033902A1 (fr)
DK (1) DK1765776T3 (fr)
ES (1) ES2315887T3 (fr)
HK (1) HK1104295A1 (fr)
HR (1) HRP20080533T3 (fr)
IL (1) IL179067A (fr)
MX (1) MXPA06014447A (fr)
NO (1) NO20070688L (fr)
NZ (1) NZ551314A (fr)
PL (1) PL1765776T3 (fr)
PT (1) PT1765776E (fr)
RS (1) RS50684B (fr)
SI (1) SI1765776T1 (fr)
TW (1) TWI316933B (fr)
WO (1) WO2006005484A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371336B2 (en) 2002-09-24 2008-05-13 E.I. Du Pont Nemours And Company Water dispersible polyanilines made with polymeric acid colloids for electronics applications
EP1967202A1 (fr) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Utilisation d'antagonistes LHTH pour le traitement des symptômes de tractus urinaires faibles, en particulier la vessie hyperactive et/ou hyperactivité du détrusor
EP1988098A1 (fr) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Nouveaux dérivés de tétrahydrocarbazole en tant que ligands de récepteurs couplés à la protéine G
EP2095818A1 (fr) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Utilisation d'antagonistes LHRH dans des doses n'impliquant pas de castration
US9175211B2 (en) * 2010-03-03 2015-11-03 Universal Display Corporation Phosphorescent materials
US8637452B2 (en) * 2011-02-23 2014-01-28 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2016184829A1 (fr) 2015-05-18 2016-11-24 Nerre Therapeutics Limited Antagonistes doubles des récepteurs nk-1/nk-3 pour le traitement de maladies dépendant des hormones sexuelles
EP3765024B1 (fr) 2018-03-14 2023-11-22 KaNDy Therapeutics Limited Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1418703A (en) * 1973-06-02 1975-12-24 Pfizer Ltd 3-alkyl-9-substituted-1,2,3,4-tetrahydrocarbazoles
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
EP0603432B1 (fr) 1992-12-18 1998-10-21 Smithkline Beecham Plc Dérivés du tétrahydrocarbazole pour la préparation de médicaments pour traiter des maladies où on agoniste de la 5-HT1 est indiqué
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US5607939A (en) 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
UY23948A1 (es) 1995-02-08 2001-10-25 Takeda Chemical Industries Ltd Derivados de anillos condensados de tiofeno su producción y uso.
WO1997014697A1 (fr) 1995-10-19 1997-04-24 Takeda Chemical Industries, Ltd. DERIVES DE THIENOPYRIDINE ANTAGONISTES DE LA gn-RH
AU7333496A (en) 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Quinoline derivatives as gnrh antagonists
AU704937B2 (en) 1995-12-14 1999-05-06 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
HUP9902121A3 (en) 1995-12-14 2001-05-28 Merck & Co Inc Indole derivatives as antagonists of gonadotropin releasing hormone and pharmaceutical compositions containing them
AU2406597A (en) 1996-04-26 1997-11-19 Takeda Chemical Industries Ltd. Thienopyridine derivatives, their production and use
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
EP0882736A1 (fr) * 1997-06-02 1998-12-09 Laboratoire Theramex S.A. Analogues peptidiques du LH-RH, leurs utilisations et compositions pharmaceutiques les contenant
JP2002502422A (ja) 1997-06-05 2002-01-22 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモンの拮抗薬
CA2292605A1 (fr) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonistes de l'hormone de liberation des gonadotrophines
CA2292881A1 (fr) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonistes de gonadoliberine
DE19728737C1 (de) 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
WO1999021553A1 (fr) 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonistes de l'hormone de liberation de la gonadothrophine
JP2002510628A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
EP1070064A1 (fr) 1998-04-02 2001-01-24 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
EP1171125A1 (fr) 1999-03-10 2002-01-16 Merck & Co., Inc. Composes 6-azaindole utilises comme antagonistes d'une hormone liberant la gonadotropine
JP2002539124A (ja) 1999-03-10 2002-11-19 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
WO2003013528A1 (fr) 2001-08-02 2003-02-20 Neurocrine Biosciences, Inc. Pyridin-4-ones substituees et leur utilisation en tant qu'antagonistes du recepteur de l'hormone de liberation de la gonadotrophine
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
RU2319692C2 (ru) 2001-12-14 2008-03-20 Центарис Гмбх Производные тетрагидрокарбазола, способ получения производных тетрагидрокарбазола (варианты), их применение (варианты) и фармацевтическая композиция, обладающая активностью антагониста гонадотропин-рилизинг-гормона (варианты)
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant

Also Published As

Publication number Publication date
AR050347A1 (es) 2006-10-18
AU2005261930B2 (en) 2008-12-11
US7375127B2 (en) 2008-05-20
PL1765776T3 (pl) 2009-01-30
JP4746617B2 (ja) 2011-08-10
EP1995238A2 (fr) 2008-11-26
IL179067A0 (en) 2007-03-08
US8067456B2 (en) 2011-11-29
CY1110415T1 (el) 2015-04-29
EP1765776B1 (fr) 2008-08-27
CN1997629A (zh) 2007-07-11
CN1997629B (zh) 2011-08-03
JP2008505947A (ja) 2008-02-28
WO2006005484A1 (fr) 2006-01-19
US20080280965A1 (en) 2008-11-13
CA2565850A1 (fr) 2006-01-19
SI1765776T1 (sl) 2008-12-31
BRPI0513209A (pt) 2008-04-29
PT1765776E (pt) 2008-11-04
TWI316933B (en) 2009-11-11
EP1765776A1 (fr) 2007-03-28
US20060014818A1 (en) 2006-01-19
ES2315887T3 (es) 2009-04-01
TW200616955A (en) 2006-06-01
KR100888895B1 (ko) 2009-03-17
DK1765776T3 (da) 2008-12-15
HRP20080533T3 (en) 2008-12-31
AU2005261930A1 (en) 2006-01-19
ATE406352T1 (de) 2008-09-15
NZ551314A (en) 2009-09-25
DE102004033902A1 (de) 2006-02-16
CA2565850C (fr) 2011-05-10
IL179067A (en) 2013-08-29
RS50684B (sr) 2010-06-30
DE502005005206D1 (de) 2008-10-09
NO20070688L (no) 2007-03-26
MXPA06014447A (es) 2007-03-01
EP1995238A3 (fr) 2009-09-02
KR20070035036A (ko) 2007-03-29

Similar Documents

Publication Publication Date Title
HK1104295A1 (en) Tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs)
IL200851A0 (en) Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors
ZA200800405B (en) Pyrisazinone derivatives as thyroid hormone receptor agonists
TWI318626B (en) Indole derivatives exhibiting pgd2 receptor antagonism
GB0607196D0 (en) G-protein coupled receptor agonists
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
ZA200610416B (en) Indole derivatives as histamine receptor antagonists
EP2650009B8 (fr) Procédés de criblage utilisant les récepteurs couplés à la protéine G et compositions associées
IL188039A0 (en) Oxindole derivatives
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
EP1940843A4 (fr) Derives heterocycliques insatures
EP2370098A4 (fr) Anticorps contre les récepteurs de guanylyle cyclase
ZA200904363B (en) Substituted oxindole derivatives and their use as vasopressin receptor ligands
PL2568045T3 (pl) Zmutowane receptory sprzężone z białkiem g i sposoby ich wytwarzania
ZA200604791B (en) Hydronopol derivatives as agonists on human ORL1 receptors
SI1833791T1 (sl) Derivati 2 3 4 9-tetrahidro-1h-karbazola kot antagonisti receptorja crth2
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
HK1095808A1 (zh) 硫代聯芳基甲基亞磺酰基衍生物
GB2423085B (en) Ligands for G-protein coupled receptors
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
IL161626A0 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
ZA200609436B (en) Novel tetrahydrocarbazole derivates with improved biological action and improved solubility as ligands for G-Protein coupled receptors (GPCRS)
TH102377B (th) Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of g-protein couples receptors (gpcrs)
GB2467060B (en) Ligands for G-protein coupled receptors
IL175347A0 (en) Hydronopol derivatives as agonists on human orl1 receptors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150705